Refine by
Platelet Articles & Analysis
31 news found
Every 2 seconds someone in the U.S. needs blood and or platelets. Blood donations are critical to helping to save lives. We place a high level of importance on being an involved member in our community because when our employees are thriving, AVTECH is thriving. ...
On Wednesday, June 7th, during the Providence Business News 2023 Best Places To Work awards ceremony, AVTECH Software was awarded third place within the Small Business category. This is the third consecutive year that our team has received the Best Places To Work Award. It is once again a huge honor for us to be acknowledged for creating a positive work environment, where our employees love to ...
All patients required therapy because of dangerous narrowing of the carotid artery and received the nowadays standard basic therapy with the blood platelet inhibitors acetylsalicylic acid (Aspirin©) and/or clopidogrel to prevent renewed vascular occlusion (thrombosis). ...
The result is a reduction in red blood cells, which can cause weakness and fatigue, and in platelets, which increases the risk of bleeding due to deficient clotting. ...
The result is a reduction in red blood cells, which can cause weakness and fatigue, and in platelets, which increases the risk of bleeding due to deficient clotting. ...
Coating materials can attract and retain moisture and impart lubricating quality, thereby reducing the damage caused by consumable entry into the human body, improving the performance of these invasive procedures, as well as reducing protein adsorption while reducing platelet activation. CD Bioparticles is committed to supplying a full range of medical coating products with ...
Oyster peptide Oyster peptides can help regulate blood lipids, inhibit platelet aggregation, relieve hyperglycemia, improve immunity, as well as protect and promote liver metabolism. ...
The most common laboratory abnormalities(≥20%) were increased phosphate, increased creatinine, decreased hemoglobin, increased glucose, increased calcium, decreased sodium, decreased phosphate, increased alanine aminotransferase, increased alkaline phosphatase, decreased lymphocytes, increased aspartate aminotransferase, decreased platelets, increased activated partial ...
Two of the main types of regenerative therapy include prolotherapy and platelet rich plasma. Both work to stimulate the body’s natural healing process leading to a natural recovery, but platelet rich plasma (PRP) contains about six times the concentration of a person’s own platelets which can accelerate the tissue repair and ...
Symptoms are severe including highly penetrable pulmonary fibrosis, oculocutaneous albinism, and bleeding due to platelet dysfunction, and colitis. HPS-related pulmonary fibrosis occurs early in life (30’s-40’s) and patients have a 10-12 year mean survival rate. ...
Fondaparinux sodium can be used in anti-thrombotic applications. Eptifibatide can serve as a platelet aggregation inhibitor. The ferric ammonium citrate provided is of pharmaceutical secondary standard and tirofiban hydrochloride is of medical grade. ...
Chemotherapy drugs may reduce patients’ platelet and white blood cell counts and weaken their immune systems. This leaves them more vulnerable to wound infections. ...
The company is applying its proprietary cell stabilization technology first to platelets, to develop lifesaving products. Its lead investigational product is Thrombosomes®, a freeze-dried hemostatic derived from human platelets. ...
JELMYTO can affect your bone marrow and can cause a decrease in your white blood cell, red blood cell, and platelet counts. Your healthcare provider will do blood tests prior to each treatment to check your blood cell counts during treatment with JELMYTO. ...
She is internationally recognized for her scientific accomplishments (publications, patents, and invited lectures) in the field of thrombosis and cardiovascular disease, having cloned the platelet P2Y12 receptor, target of a $6B drug. Dr. Conley was the collaborative scientific leader in development and approval of Andexxa® (andexanet alfa, approved May 2018), a ...
AVM-NKT cells home to abnormal cells including cancer and autoreactive lymphocytes sparing platelets, red blood cells and stem cells. These unique AVM-NKT cells could play a significant role in addressing several serious conditions, including various types of cancer and autoimmune diseases such as type 1 diabetes. ...
GS-248 provides a combination of anti-inflammatory, vasodilatory and platelet inhibitory effects by potently and selectively inhibiting microsomal prostaglandin E synthase-1 (mPGES-1). ...
Cellphire Therapeutics, Inc., a biotechnology company developing next-generation platelet-based hemostatic therapeutics for application across multiple medical indications, announced today that the first patient has been dosed in the company’s Phase 2 dose-ranging study of Thrombosomes®, a platelet-based freeze-dried hemostatic agent, in bleeding ...
AVM0703 targets lymphoma while sparing normal lymphocytes, platelets, red blood cells, and stem cells. AVM believes this treatment could reduce the need for transfusions, lower the costs of cancer care associated with managing treatment side-effects, and improve quality of life for lymphoma patients. ...
Götz Münch, CEO of advanceCOR, summarizes: „ This is remarkable because patients were already maximally treated with standard platelet inhibitors. And there was an additional effect of Revacept on platelet inhibition. ...